Pharma RSS Digest - 2026-04-20

Overview

Monday's pharma news flow is dominated by company-specific catalysts ahead of a key clinical data readout and a notable medtech funding event. Nektar Therapeutics is scheduled to present 52-week topline results from the 16-week extension period of its REZOLVE-AA Phase 2b trial for rezpegaldesleukin in severe-to-very-severe alopecia areata, an investigational regulatory T-cell proliferator representing a novel approach to treating autoimmune conditions. In medtech, Pulnovo Medical completed a $100 million oversubscribed financing round with Medtronic as the lead strategic investor, alongside a commercial agreement that could leverage Medtronic's global distribution capabilities for Pulnovo's pulmonary artery denervation system. The 10x Genomics Atera spatial transcriptomics platform launch at AACR provides a research tools angle, though it remains peripheral to therapeutic development headlines. With alert counts at zero and limited broader sector themes, the window reflects a quiet trading period driven by individual company catalysts.

Key Developments

Nektar Therapeutics will host an investor call and live webcast on April 20, 2026 to present 52-week topline results from the 16-week extension treatment period of its ongoing Phase 2b REZOLVE-AA clinical trial evaluating rezpegaldesleukin in severe-to-very-severe alopecia areata. The drug candidate targets regulatory T-cells, a mechanism that could address an unmet medical need given the limited treatment options available for severe cases of this autoimmune condition. Results will be released via morning press release and the webcast replay will be available for at least 30 days following the event. What to watch next: specific efficacy and safety data from the extension period, which will determine whether Nektar can advance the asset toward later-stage development.

Source: PR Newswire Health

Pulnovo Medical announced completion of a $100 million oversubscribed strategic financing round on April 19, 2026, with Medtronic joining as the leading investor alongside existing backers including EQT, Qiming Venture Partners, OrbiMed, and Lilly Asia Ventures, with HSG (formerly Sequoia China) as a new investor. Medtronic and Pulnovo also entered into a commercial agreement for potential future product commercialization leveraging Medtronic's global commercial capabilities. Pulnovo's PADN (Pulmonary Artery Denervation) System has been used in approximately 1,500 procedures globally and holds regulatory approvals in seven countries, plus FDA Breakthrough Device designation with two fully approved IDE trials underway led by Dr. Gregg Stone from Mount Sinai. The deal signals Medtronic's validation of the PADN approach for treating pulmonary hypertension and heart failure. What to watch next: whether the partnership yields a clearer timeline for US market entry and how commercialization proceeds in the EU, Middle East, and China.

Source: PR Newswire Health

Watchlist

• 10x Genomics unveiled Atera, calling it the "biggest launch in the company's history," a spatial instrument enabling whole-transcriptome analysis at scale with 4x throughput and higher plex capacity compared to the Xenium platform, debuted at the AACR annual meeting. The $495,000 instrument represents a research tools play rather than a therapeutic catalyst, though spatial transcriptomics increasingly informs oncology drug development.

Source: GeneEngNews